Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Vikings proposed stock and convertible-note offering is driving discussion, with traders weighing dilution and its timing after strong VK2735 maintenance data against the added funding for clinical development and potential commercialization. Reactions are split between frustration over the financing and support for the longer runway it could provide.

A looming lockup expiration and SpaceX COO Gwynne Shotwells disclosed planned share sale are fueling concern about increased stock supply, alongside criticism that the valuation is stretched. Bulls argue the sale was preplanned and is small relative to the company, with dip-buying and anticipation of the next Starship flight providing counterpoints.

GOOGLs sharp selloff has traders debating whether Metas Muse and other AI rivals threaten Googles search and discovery businesses, with some also pointing to higher yields and broader market pressure. Others call the drop an overreaction and are buying the dip, while many say there is no clear single catalyst.

McDonalds shares are under pressure after managements investor-day growth plan was overshadowed by warnings that sticky inflation and weak restaurant traffic may persist, alongside a cautious outlook for its U.S. business. Traders debate whether franchise and restaurant investments signal costly, slow growth or create a buying opportunity, with some calling the selloff excessive and others citing consumer strain and elevated menu prices.

Unusual bullish call activity is fueling speculation about a possible Unity buyout, with traders floating potential suitors including AppLovin and AI companies; no deal is confirmed. Some also point to an upcoming Meta VR event as a possible catalyst, while others view the options flow as a speculative bet that may not lead to news.

FDA scrutiny of GLP-1 weight-loss drugs and concerns about Hims exposure to compounded treatments are a prominent focus, with some traders viewing the headlines as a risk while others call them temporary and point to Australia expansion and branded Wegovy as offsets. The discussion also reflects frustration with HIMS volatile, range-bound trading.

Arcturus OTC deficiency Phase 2 update and plans to use its LUNAR 2.0 platform for ARCT-2601 are drawing attention, alongside its myNEO acquisition. Traders see the stronger-expression technology and trial findings as encouraging, while others are concerned about a delayed timeline and higher spending.

POETs updated investor presentation and ECOC conference activity have fueled attention, but traders are focused on whether the company will provide concrete production, shipment, or order updates after promising September announcements. Some view the technology and award buzz positively, while others are disappointed that the presentation did not include hard commercial progress.

XCNs move above the half-cent level has fueled breakout and momentum chatter, with bullish traders pointing to Onyxs completed Chain technology acquisition and plans for payments and a neobank. Others warn the spike may be a low-volume pump-and-dump rather than a sustained move.